TISSIUM
France, Paris, Ile-de-France
About TISSIUM
TISSIUM is a clinical and commercial-stage medtech company developing a proprietary platform of fully biosynthetic, biomorphic, programmable elastomeric polymers for atraumatic, sutureless tissue repair and reconstruction. Its pipeline spans peripheral nerve repair, hernia repair, and cardiovascular sealants, with lead product COAPTIUM CONNECT having received FDA marketing authorization. Founded in 2013 on technology from the MIT labs of Robert Langer and Jeff Karp, the company is headquartered in Paris with operations in Cambridge, USA and a manufacturing site in Roncq, France.
Latest Funding
Series C+Announced 2026-06-24
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
3 signals · where the capital is going
Capital supports the commercial rollout of COAPTIUM CONNECT in the US market following FDA marketing authorization.
globenewswire.com
+2 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to TISSIUM? You're in the right place.
Knowing they raised is the start. The edge is what's attached to TISSIUM.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of TISSIUM, and who are their main competitors?
Sign up free to ask AI about TISSIUM
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Tech Stack
MySQL
imagesLoaded
PHP
Key Highlights
AI InsightsPart of a broader €60M package: the €30M Series D2 equity (completed end of 2025) sits alongside a separate €30M financing facility from the European Investment Bank, available in three €10M tranches tied to commercial, clinical and financing milestones, with the first tranche expected to be drawn by end of June 2026.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to TISSIUM
Selling to TISSIUM? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to TISSIUM.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.